[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anticoagulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anticoagulation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,79,104,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100584513","timing-of-anticoagulant-administration-during-radial-access-percutaneous-coronary-intervention-the-hera-pci-study-heparin-early-for-radial-access-percutaneous-coronary-intervention-100584513",false,"NCT06890312","Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)","HERA-PCI","Inclusion Criteria:\n\n* Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention\n* Subject affiliated to a social protection health insurance\n* Subject able to understand the objectives and risks of the research and to provide dated and signed consent\n* Subject who has been informed of the results of the preliminary medical examination\n\nExclusion Criteria:\n\n* Contraindication to the use of heparin (history of heparin-induced thrombocytopenia)\n* Very high bleeding risk defined by recent bleeding (\\\u003C6 months) of type 3 of the BARC classification\n* Subject in an exclusion period (determined by a previous or ongoing study)\n* Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)\n* Subject under safeguard of justice\n* Subject under guardianship or curatorship\n* Pregnancy\n* Breastfeeding\n* Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).","ALL","18 Years",{"count":19,"type":20},550,"ESTIMATED","INTERVENTIONAL",[23],"NA","While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.",[26,27,28,29,30],"Coronary Angiography","Percutaneous Coronary Intervention","Radial Artery Occlusion","Bleeding","Anticoagulation",[32,33,34,35,36],"Anticoagulant injection timing","Percutaneous coronary intervention","Coronary angiography","Radial artery occlusion prevention","Bleeding events","RECRUITING","2026-05-20",{"date":40,"type":41},"2026-05-26","ACTUAL",{"date":43,"type":41},"2025-06-05",{"date":45,"type":20},"2028-01",{"name":47,"class":48},"University Hospital, Strasbourg, France","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":49},"100499362","phase-4-antithrombotic-therapy-after-coronary-artery-bypass-grafting-combined-with-coronary-endarterectomy-100499362","NCT05782270","Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy","Comparison of Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy","Inclusion Criteria:\n\n* Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period.\n* No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin.\n* Must be able to swallow tablets after the surgery.\n\nExclusion Criteria:\n\n1. Patients with high bleeding risk (HAS-BLED ≥ 3);\n2. Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoing cardiac surgery for the second time;\n3. Emergency surgery;\n4. Serum creatinine \\>130μmol\u002FL, or significant liver dysfunction (elevated ALT and\u002For AST);\n5. History of digestive or urinary tract bleeding, active gastric bleeding caused by gastric ulcer, or postoperative new-onset gastric bleeding;\n6. History of hemorrhagic stroke, or platelet dysfunction;\n7. Allergic or with contraindication to any of aspirin, clopidogrel or warfarin;\n8. Participated in other clinical trial for drug or device within 30 days;\n9. Pregnant or planning to be pregnant.",{"count":58,"type":20},202,[60],"PHASE4","Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.",[30,63],"Coronary Endarterectomy",[65,66,67,68],"coronary endarterectomy","coronary artery bypass grafting","anticoagulation","antiplatelet","2025-11-17",{"date":71,"type":41},"2025-11-18",{"date":73,"type":41},"2023-04-11",{"date":75,"type":20},"2026-05-30",{"name":77,"class":78},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100565676","phase-4-point-of-care-testing-poct-for-guided-precision-anticoagulation-with-warfarin-a-multicenter-non-concurrent-controlled-study-100565676","NCT06645275","Point-of-Care Testing (POCT) for Guided Precision Anticoagulation With Warfarin: A Multicenter, Non-concurrent Controlled Study","Inclusion Criteria:\n\n* Age ≥18 years, gender unrestricted;\n* Inpatients in the cardiology department and cardiovascular surgery department who are using warfarin for the first time and require continuous treatment for at least 3 months;\n* The patient or legal guardian agrees to the research plan and signs an informed consent form;\n\nExclusion Criteria:\n\n* Patients with contraindications to anticoagulant therapy or those who are scheduled for surgery in the near future;\n* Known genotypes CYP2C9 or VKORC1;\n* Patients scheduled to undergo interventional procedures (such as radiofrequency ablation, cardiac defibrillation) in the near future;\n* Patients with hematological disorders, bleeding disorders, or a tendency to bleed;\n* Patients with severe liver and kidney dysfunction (CrCl \\\u003C 15ml\u002Fmin);\n* Patients with concurrent tumors, severe immune system diseases, or other terminal diseases;\n* Patients with severe heart failure (NYHA Class IV) or severe anemia (hemoglobin \\\u003C 60g\u002FL);\n* Pregnant and lactating women;\n* Uncontrolled hypertension (systolic blood pressure \\> 180mmHg or diastolic blood pressure \\> 120mmHg).",{"count":86,"type":20},416,[60],"This study aims to compare the key clinical indicators such as the time to achieve INR target, frequency of dose adjustment, and the incidence of thrombotic and hemorrhagic events between Point-of-Care Testing (POCT) and pyrosequencing technology in the precision dosing of warfarin, in order to assess whether POCT-based warfarin genetic testing is beneficial for improving the quality of anticoagulation treatment for patients.",[30],[91,92,93],"warfarin","POCT","Genetic test","NOT_YET_RECRUITING","2024-10-14",{"date":97,"type":41},"2024-10-16",{"date":99,"type":20},"2025-01-01",{"date":101,"type":20},"2026-03-31",{"name":103,"class":48},"RenJi Hospital",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100552685","phase-4-efficacy-and-safety-of-rivaroxaban-in-the-early-postoperative-period-for-patients-with-bioprosthetic-valves-100552685","NCT06476301","Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves","Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves: A Prospective, Randomized, Controlled Non-Inferiority Trial","Inclusion Criteria:\n\n* Aged between 18 and 80 years\n* Patients who underwent successful surgical bioprosthetic valve replacement or repair to either the mitral, aortic position or both\n* Signed informed consent\n\nExclusion Criteria:\n\n* Aged below 18 or over 80 years\n* Mechanical heart valves (MHV)\n* Bioprosthetic valve transcatheter valve replacement (TAVR)\n* Hemorrhage risk-related criteria\n\n  1. Active internal bleeding\n  2. Major surgical procedure or trauma within 30 days before the randomization visit\n  3. History of intracranial, intraocular, spinal, gastrointestinal, or atraumatic intra-articular bleeding\n  4. Chronic hemorrhagic disorder\n  5. Planned invasive procedure with potential for uncontrolled bleeding, including major surgery\n* Concomitant conditions and therapies\n\n  1. Clinically overt stroke within the past 3 months\n  2. Major surgery within 1 month\n  3. Acute coronary syndrome within 1 month\n  4. Active infective endocarditis\n  5. Severe hepatic impairment、hepatic disease associated with coagulopathy or Moderate and severe hepatic impairment (Child-Pugh Class B or C)\n  6. Uncontrolled severe hypertension\n  7. Active malignancy\n* Medication-related\n\n  1. Hypersensitivity or contraindications to Rivaroxaban, VKA, heparin.\n  2. Concomitant treatment with strong inhibitors of both CYP3A4 and P-gp (e.g., azole antifungals, such as ketoconazole and itraconazole, or HIV protease inhibitors, such as ritonavir)\n  3. Concomitant treatment with strong inducers of CYP3A4 (e.g., carbamazepine, phenytoin, rifampin, etc.)\n* HAS-BLED score\\>3\n* Others\n\n  1. Abnormal local laboratory results, such as Platelet count \\\u003C 50 x109\u002FL、Hemoglobin \\\u003C 8 g\u002FdL (5 mmol\u002FL)\n  2. Female subjects of childbearing potential without using adequate contraception、\n  3. Female pregnant or breast-feeding\n  4. Participation is not likely to comply with the study procedures or will complete follow-up\n  5. Participation in another clinical trial that potentially interferes with the current study\n  6. Life expectancy less than 6 months beyond the targeted last visit","80 Years",{"count":113,"type":20},250,[60],"this study aims to comprehensively evaluate the efficacy and safety profiles of rivaroxaban and warfarin during the initial postoperative period following surgical bioprosthetic valve in patients.",[30],[91,118,119,67],"rivaroxaban","Bioprosthetic valve","2024-06-26",{"date":122,"type":41},"2024-06-28",{"date":124,"type":20},"2024-08-01",{"date":126,"type":20},"2026-12-31",{"name":103,"class":48},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100532214","prolonged-anticoagulation-therapy-on-the-prognosis-of-patients-with-left-ventricular-thrombosis-100532214","NCT06209892","Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis","Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular","Inclusion Criteria:\n\n①Patients who have been clearly diagnosed with left ventricular thrombus by inpatient or outpatient cardiac ultrasound (including general ultrasound and acoustic imaging).\n\n②Age \\>= 18 years old\n\nExclusion Criteria:\n\n* Patients do not agree to participate in the study or have poor compliance in the past\n\n  * Contraindication to anticoagulation or allergy to anticoagulants ③Have received oral anticoagulation after diagnosis of left ventricular thrombus.\n\n    * Have undergone or are planning to undergo surgical procedures including left ventricular appendage thrombectomy, heart transplantation, ventricular wall tumor collapse, or valve replacement.\n\n      * Presence of other long-term indications for anticoagulation, such as mechanical valve implantation, atrial fibrillation, etc.\n\n        * Requirement for treatment with Tegretol and inability to change to clopidogrel bisulfate ⑦Presence of known malignant tumors, severe hepatic dysfunction (Child-Pugh classification B or less), severe renal dysfunction (creatinine clearance \\\u003C30ml\u002Fmin), anemia (Hb \\\u003C100g\u002FL), coagulation disorders and other underlying diseases, or life expectancy \\\u003C3 years ⑧ Female patients are pregnant or breastfeeding ⑨ Patients with antiphospholipid syndrome",{"count":136,"type":20},220,[23],"A single-center, open-label, exploratory randomized controlled study is proposed with the following objectives: whether prolonging the duration of anticoagulation to 12 months, compared with 6 months of routine anticoagulation, helps to reduce major adverse cardiovascular and cerebrovascular events in patients with left ventricular thrombosis and to reduce recurrence of thrombosis, as well as to assess their bleeding risk.\n\nPatients with a definite diagnosis of left ventricular thrombus and age ≥18 years were included in cardiac ultrasound (including general ultrasound and sonography) and other examinations during hospitalization and outpatient visits. Exclusion criteria were detailed in the study protocol.\n\nGROUPING: According to the duration of anticoagulation, they were divided into extended anticoagulation group (12 months) and conventional anticoagulation group (6 months).\n\nINTERVENTION: This study is planned to extend the administration of rivaroxaban (Pulsatilla) 20 mg to 12 months in the experimental group. The conventional anticoagulation group will take the drug for 6 months Study Endpoints: The primary efficacy endpoint is a major cardiovascular-vascular adverse event at 1 year; the primary safety endpoint is bleeding of grade 3 or higher as defined by the BARC classification at 1 year.\n\nPatient Follow-up Program: Subjects will require a total of 12 on-site follow-up visits (one per month) for safety evaluation, efficacy evaluation, medication adherence evaluation, and imaging follow-up at months 3, 6, and 12.",[140,30],"Embolism and Thrombosis","2024-01-06",{"date":143,"type":41},"2024-01-18",{"date":145,"type":20},"2024-01",{"date":147,"type":20},"2027-12",{"name":149,"class":48},"Chinese Academy of Medical Sciences, Fuwai Hospital"]